ZA200401108B - Biologically active peptides - Google Patents
Biologically active peptides Download PDFInfo
- Publication number
- ZA200401108B ZA200401108B ZA200401108A ZA200401108A ZA200401108B ZA 200401108 B ZA200401108 B ZA 200401108B ZA 200401108 A ZA200401108 A ZA 200401108A ZA 200401108 A ZA200401108 A ZA 200401108A ZA 200401108 B ZA200401108 B ZA 200401108B
- Authority
- ZA
- South Africa
- Prior art keywords
- peptide
- amino acid
- acid sequence
- group
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 237
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 49
- 230000012010 growth Effects 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 208000006454 hepatitis Diseases 0.000 claims description 18
- 231100000283 hepatitis Toxicity 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 201000008383 nephritis Diseases 0.000 claims description 18
- 208000002672 hepatitis B Diseases 0.000 claims description 17
- 230000005965 immune activity Effects 0.000 claims description 16
- 230000002068 genetic effect Effects 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 6
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 98
- 235000002639 sodium chloride Nutrition 0.000 description 92
- 239000011780 sodium chloride Substances 0.000 description 92
- 210000004027 cell Anatomy 0.000 description 31
- 108010034465 CMS 024 Proteins 0.000 description 26
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 108010050904 Interferons Proteins 0.000 description 16
- 102000014150 Interferons Human genes 0.000 description 16
- 229940079322 interferon Drugs 0.000 description 16
- 108010085335 Pro-Thr-Thr-Lys-Thr-Tyr-Phe-Pro-His-Phe Proteins 0.000 description 15
- 230000037396 body weight Effects 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000012980 RPMI-1640 medium Substances 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 13
- 210000000822 natural killer cell Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 230000002399 phagocytotic effect Effects 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000711975 Vesicular stomatitis virus Species 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- 241001504469 Anthus Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- -1 CMS027 Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ORYMMTRPKVTGSJ-XVKPBYJWSA-N Gln-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O ORYMMTRPKVTGSJ-XVKPBYJWSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- QBFONMUYNSNKIX-AVGNSLFASA-N Pro-Arg-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QBFONMUYNSNKIX-AVGNSLFASA-N 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- JTWIMNMUYLQNPI-WPRPVWTQSA-N Val-Gly-Arg Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N JTWIMNMUYLQNPI-WPRPVWTQSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005316 response function Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90449201A | 2001-07-13 | 2001-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200401108B true ZA200401108B (en) | 2006-05-31 |
Family
ID=25419251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200401108A ZA200401108B (en) | 2001-07-13 | 2004-02-11 | Biologically active peptides |
| ZA200509838A ZA200509838B (en) | 2001-07-13 | 2005-12-05 | Biologically active peptides |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509838A ZA200509838B (en) | 2001-07-13 | 2005-12-05 | Biologically active peptides |
Country Status (24)
| Country | Link |
|---|---|
| EP (3) | EP1947109A3 (da) |
| JP (3) | JP4213581B2 (da) |
| KR (2) | KR100889993B1 (da) |
| AT (2) | ATE414099T1 (da) |
| AU (1) | AU2002319423B2 (da) |
| BR (1) | BR0210252A (da) |
| CA (2) | CA2707767C (da) |
| DE (2) | DE60229883D1 (da) |
| DK (2) | DK1790655T3 (da) |
| ES (2) | ES2316586T3 (da) |
| HK (2) | HK1066552A1 (da) |
| IL (2) | IL159827A0 (da) |
| MX (1) | MXPA03011190A (da) |
| MY (1) | MY138219A (da) |
| NO (2) | NO332061B1 (da) |
| NZ (3) | NZ544079A (da) |
| PL (2) | PL208666B1 (da) |
| PT (2) | PT1790655E (da) |
| RU (2) | RU2305107C2 (da) |
| SA (1) | SA04240478B1 (da) |
| SG (2) | SG142165A1 (da) |
| UA (1) | UA83989C2 (da) |
| WO (1) | WO2003006492A2 (da) |
| ZA (2) | ZA200401108B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1210298C (zh) | 2001-07-13 | 2005-07-13 | 一泰医药研究（深圳）有限公司 | 序列号1的生物活性肽 |
| WO2004055042A1 (en) * | 2002-12-18 | 2004-07-01 | Pepharm R & D Limited | Biologically active peptide conjugates |
| TWI322815B (en) * | 2003-06-26 | 2010-04-01 | Cms Peptides Patent Holding Company Ltd | Biologically active peptide comprising tyrosyl-seryl-valine (ysv) |
| TWI353252B (en) * | 2004-04-28 | 2011-12-01 | Cms Peptides Patent Holding Company Ltd | Biologically active peptide vapeehptllteaplnpk der |
| CN1799623B (zh) * | 2005-01-05 | 2011-01-26 | 康哲医药研究(深圳)有限公司 | 生物活性肽在制备用于防治关节炎的药物中的用途 |
| RU2423375C2 (ru) * | 2005-07-26 | 2011-07-10 | СиЭмЭс ПЕПТАЙДЗ ПЭЙТЕНТ ХОЛДИНГ КОМПАНИ ЛИМИТЕД | Новые биологически активные пептиды и их новое применение |
| GB0918579D0 (en) | 2009-10-22 | 2009-12-09 | Imp Innovations Ltd | Gadd45beta targeting agents |
| RU2615908C1 (ru) * | 2016-05-16 | 2017-04-11 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242821A (en) | 1989-07-10 | 1993-09-07 | Valio, Finnish Co-Operative Dairies' Association | Lactococcus promoter and signal sequences for expression in bacteria |
| IT1231156B (it) | 1989-07-19 | 1991-11-19 | Eniricerche Spa | Espressione e secrezione di interleuchina 1 beta umana matura in bacillus subtilis e mezzi e metodi per il suo ottenimento. |
| WO1991009613A1 (en) * | 1989-12-22 | 1991-07-11 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Synthetic peptides as modulators of functional responses of intact cells |
| US5556744A (en) * | 1992-05-29 | 1996-09-17 | The Trustees Of The University Of Pennsylvania | Methods and compositions for diagnosing and treating certain HIV infected patients |
| DE69433299T2 (de) | 1993-06-15 | 2004-09-09 | E.I. Du Pont De Nemours And Co., Wilmington | Rekombinante spinnerseide analoge |
| JP3286420B2 (ja) | 1993-09-28 | 2002-05-27 | 株式会社ユニシアジェックス | 内燃機関の吸排気弁駆動制御装置 |
| AU2631695A (en) | 1994-06-17 | 1996-01-15 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Method for introduction of genetic material into microorganisms and transformants obtained therewith |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| US5958416A (en) * | 1994-12-16 | 1999-09-28 | Regents Of The University Of Minnesota | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease |
| IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| CA2232240C (en) | 1995-10-24 | 2007-01-16 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Peptide for inhibiting growth of smooth muscle cells |
| GB9606016D0 (en) * | 1996-03-22 | 1996-05-22 | Smithkline Beecham Plc | Novel use |
| US5861483A (en) | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| SE9603468D0 (sv) * | 1996-09-23 | 1996-09-23 | Astra Ab | New compounds |
| GB9710762D0 (en) * | 1997-05-23 | 1997-07-23 | Cancer Res Inst Royal | Binding complexes |
| WO1998054339A1 (en) | 1997-05-27 | 1998-12-03 | Hanil Synthetic Fiber Co., Ltd. | PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE) |
| KR19990024297A (ko) | 1997-08-07 | 1999-04-06 | 오종석 | 인체 구강내 치태형성을 억제하는 신규한 유산균 |
| US6100388A (en) | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
| US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
| WO2000013025A1 (en) * | 1998-08-31 | 2000-03-09 | University Of Washington | Stable isotope metabolic labeling for analysis of biopolymers |
| US6413530B1 (en) * | 1999-04-21 | 2002-07-02 | University Of Florida Research Foundation, Inc. | Pesticidal peptides |
| FR2794370B1 (fr) * | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| WO2001032853A1 (en) * | 1999-10-29 | 2001-05-10 | Institute For Applied Biomedicine | B cell clonal toxins and methods for using the same |
-
2002
- 2002-07-11 SG SG200508362-1A patent/SG142165A1/en unknown
- 2002-07-11 RU RU2004104335/13A patent/RU2305107C2/ru active
- 2002-07-11 EP EP08005150A patent/EP1947109A3/en not_active Withdrawn
- 2002-07-11 ES ES02749008T patent/ES2316586T3/es not_active Expired - Lifetime
- 2002-07-11 MX MXPA03011190A patent/MXPA03011190A/es active IP Right Grant
- 2002-07-11 PL PL368059A patent/PL208666B1/pl unknown
- 2002-07-11 NZ NZ544079A patent/NZ544079A/en not_active IP Right Cessation
- 2002-07-11 IL IL15982702A patent/IL159827A0/xx active IP Right Grant
- 2002-07-11 RU RU2007108896/10A patent/RU2425053C2/ru not_active IP Right Cessation
- 2002-07-11 PL PL383101A patent/PL211884B1/pl unknown
- 2002-07-11 DK DK07000950.1T patent/DK1790655T3/da active
- 2002-07-11 EP EP07000950A patent/EP1790655B1/en not_active Expired - Lifetime
- 2002-07-11 AU AU2002319423A patent/AU2002319423B2/en not_active Ceased
- 2002-07-11 WO PCT/GB2002/003203 patent/WO2003006492A2/en active Application Filing
- 2002-07-11 KR KR1020047000499A patent/KR100889993B1/ko not_active IP Right Cessation
- 2002-07-11 DE DE60229883T patent/DE60229883D1/de not_active Expired - Lifetime
- 2002-07-11 EP EP02749008A patent/EP1478659B1/en not_active Expired - Lifetime
- 2002-07-11 CA CA2707767A patent/CA2707767C/en not_active Expired - Fee Related
- 2002-07-11 NZ NZ553507A patent/NZ553507A/en not_active IP Right Cessation
- 2002-07-11 CA CA2452417A patent/CA2452417C/en not_active Expired - Lifetime
- 2002-07-11 DK DK02749008T patent/DK1478659T3/da active
- 2002-07-11 AT AT02749008T patent/ATE414099T1/de not_active IP Right Cessation
- 2002-07-11 PT PT07000950T patent/PT1790655E/pt unknown
- 2002-07-11 JP JP2003512262A patent/JP4213581B2/ja not_active Expired - Fee Related
- 2002-07-11 KR KR1020077013319A patent/KR100889992B1/ko not_active IP Right Cessation
- 2002-07-11 AT AT07000950T patent/ATE466871T1/de not_active IP Right Cessation
- 2002-07-11 DE DE60236330T patent/DE60236330D1/de not_active Expired - Lifetime
- 2002-07-11 SG SG2010039980A patent/SG185137A1/en unknown
- 2002-07-11 PT PT02749008T patent/PT1478659E/pt unknown
- 2002-07-11 BR BR0210252-8A patent/BR0210252A/pt active Search and Examination
- 2002-07-11 ES ES07000950T patent/ES2345842T3/es not_active Expired - Lifetime
- 2002-07-11 MY MYPI20022635A patent/MY138219A/en unknown
- 2002-07-11 UA UA2004021049A patent/UA83989C2/ru unknown
- 2002-07-11 NZ NZ529879A patent/NZ529879A/en not_active IP Right Cessation
-
2004
- 2004-01-12 NO NO20040134A patent/NO332061B1/no not_active IP Right Cessation
- 2004-01-17 SA SA04240478A patent/SA04240478B1/ar unknown
- 2004-02-11 ZA ZA200401108A patent/ZA200401108B/en unknown
- 2004-12-02 HK HK04109575.0A patent/HK1066552A1/xx not_active IP Right Cessation
-
2005
- 2005-12-05 ZA ZA200509838A patent/ZA200509838B/xx unknown
-
2007
- 2007-06-08 HK HK07106170.2A patent/HK1098767A1/xx not_active IP Right Cessation
- 2007-06-26 IL IL184227A patent/IL184227A/en not_active IP Right Cessation
- 2007-07-19 JP JP2007187713A patent/JP2007312785A/ja active Pending
- 2007-07-25 NO NO20073914A patent/NO20073914L/no not_active Application Discontinuation
-
2008
- 2008-05-29 JP JP2008140488A patent/JP4316651B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366742C (zh) | Il-2选择性激动剂和拮抗剂 | |
| EP1315513B1 (en) | "pseudo"-native chemical ligation | |
| RU2292352C2 (ru) | Ингибитор и стимулятор пролиферации стволовой клетки и их использование | |
| TW458984B (en) | Novel mutant hIL-4 proteins as antagonists or partial agonists of human interleukin 4 | |
| EA021867B1 (ru) | Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций | |
| HU218007B (hu) | Eljárás random bio-oligomer könyvtár előállítására valamint, alkalmazására | |
| EP0335423A2 (en) | Modified human G-CSF | |
| US10875903B2 (en) | Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof | |
| CN101432428A (zh) | 重组人干扰素样蛋白 | |
| EA003940B1 (ru) | Усеченный по амино-концу хемокин rantes и способы его использования | |
| JPS62174026A (ja) | 白血球減少症治療剤 | |
| ZA200401108B (en) | Biologically active peptides | |
| CN111620932A (zh) | 一种多肽及在促进nk细胞增殖和提高其对肿瘤细胞杀伤力方面的应用 | |
| CN111718399A (zh) | 一种多肽及用于nk细胞培养、制备nk细胞培养基的用途 | |
| CA2301499A1 (en) | T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof | |
| CN102131518B (zh) | 包含白介素-11类似物的生物聚合物缀合物 | |
| CN102775502A (zh) | α干扰素融合蛋白 | |
| EP0138616A2 (en) | Nona- and dodecapeptides for augmenting natural killer cell activity, processes for making them and pharmaceutical compositions comprising them | |
| CN106928335A (zh) | 用于肿瘤的Her-2多肽、组合物及制备方法和应用 | |
| JP2000264900A (ja) | 新規生理活性ペプチド | |
| CN111499723B (zh) | 一种嵌合抗原受体及其应用 | |
| CN101142234A (zh) | 结合红细胞生成素受体的新肽 | |
| CN102168057B (zh) | 表达多活性肽的工程菌及制备混合多肽的方法 | |
| JPH0474197A (ja) | 新規な免疫調整生理活性ペプチド | |
| RU2601126C2 (ru) | Способ получения биологически активных пептидов |